Skip to content
PurityIQAll posts

Additives/Preservatives

BHA Has Carried a Cancer-Hazard Listing Since 1991. The FDA Just Reviewed It for the First Time.

Published August 21, 2026

Butylated hydroxyanisole, BHA, has been listed by a U.S. government program as "reasonably anticipated to be a human carcinogen" since 1991. For thirty-five years, that listing sat next to an unchanged food-additive approval. On February 11, 2026, the FDA opened its first formal safety reassessment of BHA since that listing was made.

On February 10, 2026, HHS and FDA announced a new proactive framework for re-examining food chemicals already on the market, and used it immediately: a Federal Register notice the next day, "Butylated Hydroxyanisole (BHA); Request for Information" (Docket FDA-2026-N-0302), asked manufacturers and the public for current use levels, exposure data, and any safety information not already in FDA's files. The comment period ran to April 13, 2026 and closed on schedule. FDA Commissioner Marty Makary said at the time that the agency expected to run similar reviews of BHT and azodicarbonamide next — and it did: both got their own Requests for Information on May 13, 2026, on separate dockets. As of this writing, BHA's docket shows no published findings; it remains in FDA's "Scientific Assessment" stage, the same holding pattern the newer reviews are in.

BHA and BHT are frequently discussed together, but they are not on the same regulatory clock. BHA's comment window closed in April and hasn't reopened. BHT's, opened the same week as azodicarbonamide's, was reopened on July 29, 2026 for an additional 30 days after industry said the original window was too short, and now runs to August 31, 2026. Treating the two chemicals as a single review is a mistake worth avoiding; they're on two separate dockets moving at two different speeds.

The basis for that 1991 listing is specific. The National Toxicology Program's Report on Carcinogens lists BHA based on tumors of the forestomach in rats, and in male mice and hamsters, in dietary feeding studies. The International Agency for Research on Cancer reached a related conclusion by a different route: its 1986 review found sufficient evidence of carcinogenicity in animals, and the formal Group 2B classification, possibly carcinogenic to humans, was assigned the following year. Both listings rest on the same category of animal evidence.

There's a complicating fact that belongs in the same paragraph as the listing, not buried afterward. In 2003, IARC published a technical review specifically examining whether tumors in the rodent forestomach — an organ humans do not have — are a reliable predictor of human cancer risk. Its conclusion was that this class of tumor has limited relevance to human risk assessment. IARC has never revised BHA's Group 2B classification as a result of that finding; the listing stands exactly as it did in 1987, and the human-relevance question the agency itself raised has not been formally reconciled with it. Both facts are true at once, and neither cancels the other out.

Against that record, BHA's approval hasn't moved. It remains an authorized food additive under FDA regulation, permitted at concentrations that vary by food category, from roughly 10 to 1,000 parts per million depending on use, most commonly as an antioxidant protecting fats and oils from going rancid. California lists BHA under Proposition 65, meaning products above the state's threshold carry a cancer warning; that listing has stood, unchanged, since 1990.

The European Union's position, by contrast, hasn't moved either, just in the other direction. BHA (E320) and its relative BHT (E321) remain authorized EU food additives. EFSA's most recent full safety re-evaluation, in 2011, didn't tighten the additive's status — if anything, it concluded the acceptable daily intake could be raised. Nothing in EU or EFSA records points to a fresh 2025 or 2026 reassessment of either chemical specifically; on the European side, this is old, closed business. The divergence here isn't "banned abroad" — it's two regulators who looked at largely the same animal data decades apart and reached durable, opposite comfort levels, and only the U.S. side has reopened its own file this year.

BHA and BHT are both declared ingredients, so this is a case where the label does the work. They typically appear by name, "BHA" or "butylated hydroxyanisole," "BHT" or "butylated hydroxytoluene," toward the end of an ingredient list, often attached to the fat or oil they're protecting: cereals, chips, chewing gum, and shortening are common carriers. Products formulated without them, using vitamin E or other antioxidants instead, sit on the same shelves.

PurityIQ's job here isn't to resolve a thirty-five-year-old scientific disagreement that IARC itself hasn't fully resolved. It's to put the actual record in front of you when you're holding the product: the 1991 NTP listing, the 1987 IARC classification and IARC's own 2003 finding about its relevance to humans, the California warning, and now a live FDA docket with a real deadline, cited to the primary source. No score standing in for the parts that are still genuinely unsettled.

Sources:

As of August 21, 2026.

Sources

PurityIQ puts this same public record in front of you at the shelf. Cited to source. No score. Join the early-access list.